Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study

被引：0
|
作者：
Hofmeister, Craig C.
Chari, Ajai
Cohen, Yael
Spencer, Andrew
Voorhees, Peter M.
Estell, Jane
Venner, Christopher P.
Sandhu, Irwindeep
Jenner, Matthew W.
Williams, Cathy
Cavo, Michele
Van de Donk, Niels W. C. J.
Beksac, Meral
Kuppens, Steven
Bandekar, Rajesh
Neff, Tobias
Heuck, Christoph
Qi, Ming
Goldschmidt, Hartmut
Landgren, Ola
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
510
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma
    Brighton, Timothy A.
    Khot, Amit
    Harrison, Simon J.
    Ghez, David
    Weiss, Brendan M.
    Kirsch, Andres
    Magen, Hila
    Gironella, Mercedes
    Oriol, Albert
    Streetly, Matthew
    Kranenburg, Britte
    Qin, Xiang
    Bandekar, Rajesh
    Hu, Peter
    Guilfoyle, Mary
    Qi, Ming
    Nemat, Sepideh
    Goldschmidt, Hartmut
    CLINICAL CANCER RESEARCH, 2019, 25 (13) : 3772 - 3775
  • [32] Subcutaneous Daratumumab Plus Carfilzomib and Dexamethasone (D-Kd) in Relapsed/Refractory Multiple Myeloma: An Open-label, Multicenter, Phase 2 Study (PLEIADES)
    Chari, Ajai
    Goldschmidt, Hartmut
    Yang, Shiyi
    Kosh, Michele
    Delioukina, Maria
    Qi, Ming
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E144 - E144
  • [33] B-PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
    Nadeem, Omar
    Redd, Robert A.
    Prescott, Julia
    Metivier, Amada
    Tague, Kelsey
    Romines, Veronica
    Bertoni, Meredith
    Savell, Alexandra
    Medina, Rebekah
    Distaso, Alexandra
    Leblebjian, Houry
    Mo, Clifton C.
    Laubach, Jacob P.
    Sperling, Adam S.
    Richardson, Paul G.
    Ghobrial, Irene M.
    BLOOD, 2021, 138
  • [34] Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM)
    Patel, Krina K.
    Manasanch, Elisabet E.
    Lee, Hans C.
    Ye, J. Christine
    Thomas, Sheeba K.
    Weber, Donna M.
    Becnel, Melody R.
    Gaballa, Mahmoud R.
    Bansal, Hima
    Berkova, Zuzana
    Neelapu, Sattva S.
    Haymaker, Cara L.
    Dang, Minghao
    Wang, Linghua
    Lizee, Greg
    Orlowski, Robert Z.
    BLOOD, 2024, 144 : 4737 - 4738
  • [35] A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
    Mikhael, Joseph
    Belhadj-Merzoug, Karim
    Hulin, Cyrille
    Vincent, Laure
    Moreau, Philippe
    Gasparetto, Cristina
    Pour, Ludek
    Spicka, Ivan
    Vij, Ravi
    Zonder, Jeffrey
    Atanackovic, Djordje
    Gabrail, Nashat
    Martin, Thomas G.
    Perrot, Aurore
    Bensfia, Samira
    Weng, Qilong
    Brillac, Claire
    Semiond, Dorothee
    Mace, Sandrine
    Corzo, Kathryn P.
    Leleu, Xavier
    BLOOD CANCER JOURNAL, 2021, 11 (05)
  • [36] A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
    Joseph Mikhael
    Karim Belhadj-Merzoug
    Cyrille Hulin
    Laure Vincent
    Philippe Moreau
    Cristina Gasparetto
    Ludek Pour
    Ivan Spicka
    Ravi Vij
    Jeffrey Zonder
    Djordje Atanackovic
    Nashat Gabrail
    Thomas G. Martin
    Aurore Perrot
    Samira Bensfia
    Qilong Weng
    Claire Brillac
    Dorothée Semiond
    Sandrine Macé
    Kathryn P. Corzo
    Xavier Leleu
    Blood Cancer Journal, 11
  • [37] A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF BORTEZOMIB AND DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Jakubowiak, A.
    Offidani, M.
    Pegourie, B.
    De La Rubia, J.
    Garderet, L.
    Laribi, K.
    Bosi, A.
    Marasca, R.
    Laubach, J.
    Mohrbacher, A.
    Carella, A. M.
    Singhal, A. K.
    Tsao, L. C.
    Lynch, M.
    Bleickardt, E.
    Jou, Y. M.
    Palumbo, A.
    HAEMATOLOGICA, 2015, 100 : 2 - 2
  • [38] SUBCUTANEOUS DARATUMUMAB IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE 1B STUDY (PAVO)
    Mateos, M., V
    Chari, A.
    Nah, H.
    Lokhorst, H.
    Kaufman, J. L.
    Moreau, P.
    Oriol, A.
    Plesner, T.
    Benboubker, L.
    Hellemans, P.
    Masterson, T.
    Clemens, P. L.
    Liu, K.
    San-Miguel, J.
    Usmani, S. Z.
    HAEMATOLOGICA, 2018, 103 : 32 - 33
  • [39] Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
    Larocca, Alessandra
    Montefusco, Vittorio
    Bringhen, Sara
    Rossi, Davide
    Crippa, Claudia
    Mina, Roberto
    Galli, Monica
    Marcatti, Magda
    La Verde, Giacinto
    Giuliani, Nicola
    Magarotto, Valeria
    Guglielmelli, Tommasina
    Rota-Scalabrini, Delia
    Omede, Paola
    Santagostino, Alberto
    Baldi, Ileana
    Carella, Angelo Michele
    Boccadoro, Mario
    Corradini, Paolo
    Palumbo, Antonio
    BLOOD, 2013, 122 (16) : 2799 - 2806
  • [40] B-PRISM (Precision Intervention Smoldering Myeloma): A phase II trial of combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma.
    Nadeem, Omar
    Redd, Robert
    Mo, Clifton Craig
    Laubach, Jacob
    Prescott, Julia
    Metivier, Amada
    Davie, Christine
    Bertoni, Meredith
    Murphy, Elizabeth
    Sheehan, Brian
    Tague, Kelsey
    Shrestha, Hira
    Medina, Rebekah
    Distaso, Alexandra
    Leblebjian, Houry
    Richardson, Paul G.
    Ghobrial, Irene M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345